Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

532
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
532
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.6K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.6K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

1.4K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Early Gut Microbiome-Short-Chain Fatty Acid Axis Disruption May Be Associated with Delayed Recovery in Critically Ill Children.

Nutrients·2026
Same author

Healthcare resources for inborn errors of immunity in the Asia-Pacific region.

Journal of human immunity·2026
Same author

Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study.

Journal of Korean medical science·2026
Same author

Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea.

Journal of rheumatic diseases·2026
Same author

Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine (SKYCellflu<sup>®</sup> QIV) in Children and Adolescents: A Multicenter Test-Negative Case-Control Study in Korea.

Vaccines·2026
Same author

Diagnostic Accuracy of Serological Tests for <i>Mycoplasma pneumoniae</i> Infections in Children with Pneumonia, Based on Symptom Onset.

Annals of laboratory medicine·2025

相关实验视频

Updated: Feb 28, 2026

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
08:23

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens

Published on: March 10, 2020

12.3K

评估儿童坎比洛巴克特肠结肠炎的早期宏类疗法:一项比较研究

Ho Jung Choi1, Yoon Kyung Cho1,2, Ye Ji Kim1,2

  • 1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Antibiotics (Basel, Switzerland)
|February 27, 2026
PubMed
概括

对儿科坎皮洛巴克特肠球炎的早期宏类抗生素治疗显著减少了疾病持续时间和住院时间. 这项研究支持立即使用阿齐思罗米或克拉里思罗米,以获得儿童更好的治疗结果.

关键词:
坎比洛巴克特菌肠道炎.宏化物是什么? 宏化物儿科 儿科 儿科聚合酶连锁反应 (PCR) 试验

更多相关视频

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
08:32

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

Published on: February 17, 2023

1.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.4K

相关实验视频

Last Updated: Feb 28, 2026

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
08:23

Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens

Published on: March 10, 2020

12.3K
Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates
08:32

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

Published on: February 17, 2023

1.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.4K

科学领域:

  • 儿童传染病 儿童传染病
  • 微生物学 微生物学
  • 临床药理学 临床药理学

背景情况:

  • 有限的证据支持阿齐思罗米作为儿科坎皮洛巴克特肠球炎的第一线治疗.
  • 在这种情况下,替代性宏酸的有效性还未得到充分研究.
  • 需要评估早期启动宏类药物治疗的需要.

研究的目的:

  • 评估早期宏类抗生素治疗 (症状发病后3天内) 在儿科坎比洛巴克特肠球炎中的有效性.
  • 为了比较阿齐思罗米,克拉里思罗米和没有宏类药物治疗之间的结果.
  • 评估宏类药物治疗对临床解决和住院时间的影响.

主要方法:

  • 随机对照试验比较儿科患者的阿齐思罗米辛和克拉里思罗米辛.
  • 儿童患者的回顾性队列,他们没有接受宏类抗生素进行比较.
  • 招募19岁以下的新诊断的坎皮洛巴克特肠球炎患者.

主要成果:

  • 早期的宏类药物治疗 (27 位患者) 与非宏类药物治疗 (37 位患者) 相比,与减少住院时间 (3.8 vs 4.5 天) 相关.
  • 在早期使用宏类药物时,腹持续时间 (1.8 vs. 3.4天,p < 0.001) 和发烧持续时间 (1.1 vs. 2.8天,p < 0.001) 显著减少.
  • 吐持续时间没有显著差异 (p = 0.061).

结论:

  • 在患有坎比洛巴克特肠球炎的儿童中早期开始使用类抗生素可以加速临床解决.
  • 通过加快腹,发烧和腹部疼痛的解决,治疗缩短了住院时间.
  • 这些研究结果支持使用早期的宏类药物治疗儿科坎比洛巴克特肠球炎.